Flosequinan

Flosequinan

Clinical data
ATC code	C01DB01 (WHO)
Identifiers
IUPAC name 7-fluoro-3-methanesulfinyl-1-methyl-1,4-dihydroquinolin-4-one
CAS Number	76568-02-0
PubChem CID	4474062
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H10FNO2S
Molar mass	239.267 g/mol

WikiDoc Resources for Flosequinan
Articles
Most recent articles on Flosequinan Most cited articles on Flosequinan Review articles on Flosequinan Articles on Flosequinan in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Flosequinan Images of Flosequinan Photos of Flosequinan Podcasts & MP3s on Flosequinan Videos on Flosequinan
Evidence Based Medicine
Cochrane Collaboration on Flosequinan Bandolier on Flosequinan TRIP on Flosequinan
Clinical Trials
Ongoing Trials on Flosequinan at Clinical Trials.gov Trial results on Flosequinan Clinical Trials on Flosequinan at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Flosequinan NICE Guidance on Flosequinan NHS PRODIGY Guidance FDA on Flosequinan CDC on Flosequinan
Books
Books on Flosequinan
News
Flosequinan in the news Be alerted to news on Flosequinan News trends on Flosequinan
Commentary
Blogs on Flosequinan
Definitions
Definitions of Flosequinan
Patient Resources / Community
Patient resources on Flosequinan Discussion groups on Flosequinan Patient Handouts on Flosequinan Directions to Hospitals Treating Flosequinan Risk calculators and risk factors for Flosequinan
Healthcare Provider Resources
Symptoms of Flosequinan Causes & Risk Factors for Flosequinan Diagnostic studies for Flosequinan Treatment of Flosequinan
Continuing Medical Education (CME)
CME Programs on Flosequinan
International
Flosequinan en Espanol Flosequinan en Francais
Business
Flosequinan in the Marketplace Patents on Flosequinan
Experimental / Informatics
List of terms related to Flosequinan

Overview

Flosequinan is a quinolone vasodilator. It has direct relaxing effects on peripheral arteries and veins. It is administered orally in cases of congestive heart failure in patients who are not responsive to digitalis or ACE inhibitors. It was sold under the trade name Manoplax.

It was withdrawn from the US market in October 1993 due to an increased risk of hospitalization or death.